Added to YB: 2025-08-08
Pitch date: 2025-06-22
MLTX [bullish]
MoonLake Immunotherapeutics
-58.14%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
Market Cap
$1.1B
Pitch Price
$43.41
Price Target
165.00 (+808%)
Dividend
N/A
EV/EBITDA
-3.57
P/E
-4.66
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Show full summary:
MoonLake Immunotherapeutics - $MLTX
MLTX: Sonelokimab nanobody (IL-17A/F inhibitor) shows best-in-class P2 efficacy in HS/PsA. Sep 2025 VELA P3 topline could drive 150-250% upside. $480M cash (runway to 2028), $2.5B EV. Merck acquisition interest, tri-specific design advantages. PT $165 (bull), $85 (base), $20 (bear).
Read full article (2 min)